Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers

NCT06485089 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2025-10-29

No results posted yet for this study

Summary

Evaluation of biomarkers for risk of developing breast cancer in women with obesity who are using tirzepatide to achieve weight loss.

Conditions

Interventions

DRUG

tirzepatide

Women taking tirzepatide as part of standard care in the Weight Managment Clinic

Sponsors & Collaborators

  • University of Kansas Medical Center

    lead OTHER

Principal Investigators

  • Carol J Fabian, MD · University of Kansas Medical Center

Eligibility

Min Age
40 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-09-14
Primary Completion
2026-02-28
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06485089 on ClinicalTrials.gov